PLA2G7 and coronary artery disorder: In 2014, the Food and Drug Administration sanctioned the Lp-PLA2 examination for individuals lacking prior coronary disease as a means to assess the likelihood of heart disease, cardiac arrest, and potential additional cardiac issues [22].